A detailed history of Royal Bank Of Canada transactions in Cerus Corp stock. As of the latest transaction made, Royal Bank Of Canada holds 22,050 shares of CERS stock, worth $34,839. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,050
Previous 20,586 7.11%
Holding current value
$34,839
Previous $36,000 5.56%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.7 - $2.39 $2,488 - $3,498
1,464 Added 7.11%
22,050 $38,000
Q2 2024

Aug 14, 2024

BUY
$1.62 - $2.04 $21,056 - $26,515
12,998 Added 171.3%
20,586 $36,000
Q1 2024

Nov 05, 2024

SELL
$1.66 - $2.42 $21,576 - $31,455
-12,998 Reduced 63.14%
7,588 $14,000
Q1 2024

May 15, 2024

SELL
$1.66 - $2.42 $62,739 - $91,463
-37,795 Reduced 83.28%
7,588 $14,000
Q4 2023

Feb 14, 2024

BUY
$1.25 - $2.35 $24,335 - $45,749
19,468 Added 75.12%
45,383 $98,000
Q3 2023

Nov 14, 2023

BUY
$1.5 - $3.07 $9,943 - $20,351
6,629 Added 34.37%
25,915 $41,000
Q2 2023

Aug 14, 2023

SELL
$1.79 - $2.9 $120,168 - $194,685
-67,133 Reduced 77.68%
19,286 $47,000
Q1 2023

May 15, 2023

SELL
$2.65 - $3.81 $48,328 - $69,482
-18,237 Reduced 17.43%
86,419 $256,000
Q4 2022

Feb 14, 2023

BUY
$3.38 - $4.22 $130,785 - $163,288
38,694 Added 58.66%
104,656 $381,000
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.83 $76,691 - $130,352
22,359 Added 51.28%
65,962 $237,000
Q2 2022

Aug 15, 2022

BUY
$4.41 - $5.69 $126,368 - $163,046
28,655 Added 191.7%
43,603 $230,000
Q1 2022

May 16, 2022

SELL
$4.81 - $6.99 $1,144 - $1,663
-238 Reduced 1.57%
14,948 $82,000
Q4 2021

Feb 14, 2022

SELL
$5.97 - $7.93 $21,503 - $28,563
-3,602 Reduced 19.17%
15,186 $104,000
Q3 2021

Nov 15, 2021

BUY
$4.79 - $6.68 $12,315 - $17,174
2,571 Added 15.85%
18,788 $115,000
Q2 2021

Aug 16, 2021

BUY
$5.35 - $6.35 $86,760 - $102,977
16,217 New
16,217 $95,000

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $280M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.